AVIR Aviragen Therapeutics, Inc.

1.24
-0.06  -4.62%
Previous Close 1.30
Open 1.30
Price To book 1.37
Market Cap 47.91M
Shares 38,640,000
Volume 48,989
Short Ratio 1.90
Av. Daily Volume 58,437

SEC filingsSee all SEC filings

  1. 8-K - Current report 17516262
  2. S-8 - Securities to be offered to employees in employee benefit plans 162056535
  3. 8-K - Current report 161987342
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981458
  5. 8-K - Current report 161972533

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a enrollment completed November 2016. Top-line data due during the next few weeks - as of January 9, 2017. No firm date given. Date listed in FDA Calendar is a BPC estimate only as to the latest possible date (i.e. possibly earlier).
BTA585
Respiratory syncytial virus (RSV)
Phase 2 ongoing.
BTA074 5% topical gel
Condyloma
Phase 2b top-line data due February 2017.
Vapendavir - SPIRITUS trial
Human rhinovirus (HRV)
Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Laninamivir Octanoate - IGLOO
Adults with symptomatic influenza A or B infection

Latest News

  1. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
  3. Edited Transcript of AVIR earnings conference call or presentation 3-Nov-16 8:30pm GMT
  4. AVIRAGEN THERAPEUTICS, INC. Financials
  5. Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
  6. Aviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
  7. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  8. Aviragen Therapeutics to Present at Stifel 2016 Healthcare Conference
  9. AVIRAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  10. Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q1, 2017 By the Numbers : November 7, 2016
  11. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  12. Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
  13. Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
  14. Q1 2017 Aviragen Therapeutics Inc Earnings Release - After Market Close
  15. ETF’s with exposure to Aviragen Therapeutics, Inc. : October 31, 2016
  16. Aviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
  17. Aviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
  18. ETF’s with exposure to Aviragen Therapeutics, Inc. : October 17, 2016
  19. AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. ETF’s with exposure to Aviragen Therapeutics, Inc. : October 7, 2016

SEC Filings

  1. 8-K - Current report 17516262
  2. S-8 - Securities to be offered to employees in employee benefit plans 162056535
  3. 8-K - Current report 161987342
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981458
  5. 8-K - Current report 161972533
  6. 8-K - Current report 161929100
  7. DEF 14A - Other definitive proxy statements 161904921
  8. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 161883453
  9. 8-K - Current report 161769772
  10. 8-K - Current report 161766091